<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Midazolam</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00683</strong>&#160; (APRD00680)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit</td></tr><tr><th>Description</th><td><p>A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients.  It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00683/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00683/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00683.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00683.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00683.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00683.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00683.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00683">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Midazolam</td><td>German/French/Spanish</td><td>INN</td></tr><tr><td>Midazolamum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Midazolam Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000118/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000118/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: PLYSCVSCYOQVRP-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 361.054881082</li>
              <li>Average Mass: 362.228</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000118">DBSALT000118</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Anquil</td><td>General Pharma</td></tr><tr><td>Benzosed</td><td>Pharmaceutical</td></tr><tr><td>Dalam</td><td>Richmond</td></tr><tr><td>Damizol</td><td>Specifar</td></tr><tr><td>Demizolam</td><td>Dem Ila&#231;</td></tr><tr><td>Doricum</td><td>Roche</td></tr><tr><td>Dormicum</td><td>Roche</td></tr><tr><td>Dormid</td><td>Scott</td></tr><tr><td>Dormipron</td><td>Chalver</td></tr><tr><td>Dormire</td><td>Crist&#225;lia</td></tr><tr><td>Dormitol</td><td>Square</td></tr><tr><td>Dormixal</td><td>Demo</td></tr><tr><td>Dormonid</td><td>Roche</td></tr><tr><td>Drimnorth</td><td>Northia</td></tr><tr><td>Epistatus</td><td>IFET</td></tr><tr><td>Flormidal</td><td>Galenika</td></tr><tr><td>Fulsed</td><td>Ranbaxy</td></tr><tr><td>Fulsed Injection</td><td>Terapia</td></tr><tr><td>Garen</td><td>Bio-Pharma</td></tr><tr><td>Gobbizolam</td><td>Gobbi</td></tr><tr><td>Hipnazolam</td><td>EMS</td></tr><tr><td>Hipnoz</td><td>Pharos</td></tr><tr><td>Hypnofast</td><td>Incepta</td></tr><tr><td>Hypnovel</td><td>Roche</td></tr><tr><td>Ipnovel</td><td>Roche</td></tr><tr><td>Nocturna</td><td>Lafi</td></tr><tr><td>Setam</td><td>Rimsa</td></tr><tr><td>Talentum</td><td>Fisiopharma</td></tr><tr><td>Terap</td><td>Sanitas</td></tr><tr><td>Versed</td><td>Roche</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-anxiety-agents">Anti-Anxiety Agents</a></li>
<li><a href="/mesh/hypnotics-and-sedatives">Hypnotics and Sedatives</a></li>
<li><a href="/mesh/anesthetics-intravenous">Anesthetics, Intravenous</a></li>
<li><a href="/mesh/adjuvants-anesthesia">Adjuvants, Anesthesia</a></li>
<li><a href="/mesh/gaba-modulators">GABA Modulators</a></li></ul></td></tr><tr><th>CAS number</th><td>59467-70-8</td></tr><tr><th>Weight</th><td>Average: 325.767<br>Monoisotopic: 325.078203343</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>13</sub>ClFN<sub>3</sub></td></tr><tr><th>InChI Key</th><td>DDLIGBOFAVUZHB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzodiazepines</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzodiazepines</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Chlorobenzenes; Aryl Fluorides; Aryl Chlorides; N-substituted Imidazoles; Polyamines; Organofluorides; Organochlorides</td></tr><tr><th>Substituents</th><td>fluorobenzene; chlorobenzene; aryl chloride; benzene; n-substituted imidazole; aryl fluoride; aryl halide; azole; imidazole; polyamine; organochloride; organohalogen; organofluoride; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>The midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia. </td></tr><tr><th>Pharmacodynamics</th><td>Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.</td></tr><tr><th>Mechanism of action</th><td>It is thought that the actions of benzodiazepines such as midazolam are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines increase the activity of GABA, thereby producing a calming effect, relaxing skeletal muscles, and inducing sleep. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed after oral administration. The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%. The absolute bioavailability, if given intramuscularly (IM), is greater than 90%. 
Cmax, IM = 90 ng/mL;
Tmax, IM = 0.5 hours. 
Following IM administered, Cmax for midazolam and its 1-hydroxy metabolite were approxiately one-half of those achieved after intravenous injection. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.24 to 2.02 L/kg [pediatric patients (6 months to &lt;16 years) receiving 0.15 mg/kg IV midazolam,]</li>
	<li>1 to 3.1 L/kg [intravenously administered, healthy adults] <br>
Female gender, old age, and obesity may increase the volume of distribution. Midazolam may also cross the placenta and has been detected in human milk and cerebrospinal fluid.</li>
</ul></td></tr><tr><th>Protein binding</th><td>97% protein bound. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam (also known as 1-hydroxy-midazolam), and 4-hydroxymidazolam (makes up 5% or less of the biotransformation products). 1-hydroxy-midazolam is at least as potent as the parent compound and may contributed to the overall activity of midazolam. In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. It also undergoes N-glucuronidation via UGT1A4. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Midazolam</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0004673" target="_blank">Cytochrome P450 4B1</a></li></ul></td><td><a href="/metabolites/DBMET00444">Alpha-hydroxymidazolam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/453">Details</a></td></tr><tr><td>Midazolam</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0004673" target="_blank">Cytochrome P450 4B1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00446">4-hydroxymidazolam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/455">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, &#945;-hydroxymidazolam, followed by glucuronidation of the &#945;&#8211;hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The &#945;- hydroxymidazolam glucuronide is then excreted in urine. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates. The amount of midazolam excreted unchanged in the urine when given intravenously is less than 0.5%. 45% to 57% of the dose was excreted in the urine as 1-hydroxymethyl midazolam conjugate. </td></tr><tr><th>Half life</th><td>Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)</td></tr><tr><th>Clearance</th><td><ul>
	<li>9.3 to 11 mL/min/kg [pediatric patients (6 months to &lt;16 years old)]</li>
	<li>0.25 to 0.54 L/hr/kg [intravenous, healthy adults]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9724</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5074</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5587</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7476</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7366</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7194</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.8586</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.7132</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6887</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6554</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5214</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9001</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8024
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7703
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1488 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9827
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7379
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Apothecon inc div bristol myers squibb</li>
<li>App pharmaceuticals llc</li>
<li>Astrazeneca pharmaceuticals lp</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Baxter healthcare corp anesthesia critical care</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Ben venue laboratories inc</li>
<li>Claris lifesciences ltd</li>
<li>Hospira inc</li>
<li>International medicated systems ltd</li>
<li>International medication systems ltd</li>
<li>Taylor pharmaceuticals</li>
<li>Wockhardt ltd</li>
<li>Hlr technology</li>
<li>Apotex inc richmond hill</li>
<li>Hi tech pharmacal co inc</li>
<li>Paddock laboratories inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Roxane laboratories inc</li>
<li>Hoffmann la roche inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bandbpharmaceuticals.com">B&amp;B Pharmaceuticals</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.curapharma.com">Cura Pharmaceutical Co. Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.ebewe.at">Ebewe Pharma</a></li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li>Novex Pharma</li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pharmedium.com">Pharmedium</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Parenteral</td><td></td></tr><tr><td>Syrup</td><td>Oral</td><td>2 mg/mL</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Midazolam 5 mg/ml</td><td>3.9USD</td><td>ml</td></tr><tr><td>Midazolam-nacl 2 mg/ml inj</td><td>2.31USD</td><td>ml</td></tr><tr><td>Midazolam hcl 5 mg/ml vial</td><td>1.18USD</td><td>ml</td></tr><tr><td>Midazolam-nacl 1 mg/ml inj</td><td>1.13USD</td><td>ml</td></tr><tr><td>Midazolam hcl 2 mg/ml syrup</td><td>1.08USD</td><td>ml</td></tr><tr><td>Midazolam 1 mg/ml isecure syr</td><td>0.73USD</td><td>ml</td></tr><tr><td>Midazolam hcl 1 mg/ml vial</td><td>0.26USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>159 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>0.024 mg/mL</td><td>Thorsteinn Loftsson and Dagn&#253; Hreinsd&#243;ttir, 2006</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>9.87e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.89</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.5</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>6.57</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>30.18</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>99.43</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>32.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Madhup K. Dhaon, &#8220;Process for the preparation of midazolam.&#8221; U.S. Patent US6262260, issued August, 1979.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6262260&amp;tbm=pts" target="_blank">US6262260 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Skerritt JH, Johnston GA: Enhancement of <span class="caps">GABA</span> binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6135616">Pubmed</a></li>
	<li>Isojarvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:80-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10030438">Pubmed</a></li>
	<li>Garratt JC, Gent JP, Feely M, Haigh JR: Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential? Eur J Pharmacol. 1988 Jan 5;145(1):75-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2894998">Pubmed</a></li>
	<li>Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17287588">Pubmed</a></li>
	<li>Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. <span class="caps">CNS</span> Drugs. 2004;18(5):297-328. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15089115">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00550" target="_blank">D00550 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07524" target="_blank">C07524 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4192" target="_blank">4192 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507611" target="_blank">46507611 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4047.html" target="_blank">4047 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21363" target="_blank">21363 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000241" target="_blank">DAP000241 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450496" target="_blank">PA450496 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=3342" target="_blank">3342 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3342" target="_blank">3342 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2240286" target="_blank">2240286 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/versedsyr.htm" target="_blank">http://www.rxlist.com/cgi/generic2/versedsyr.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/midazolam.html" target="_blank">http://www.drugs.com/cdi/midazolam.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Midazolam" target="_blank">Midazolam <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N05CD08<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N05#N05">N05 &#8212; PSYCHOLEPTICS</a></li><li><a href="/atc/N05C#N05C">N05C &#8212; HYPNOTICS AND SEDATIVES</a></li><li><a href="/atc/N05CD#N05CD">N05CD &#8212; Benzodiazepine derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:24.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00683.pdf?1265922739">show</a>(73.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB05631">BXT-51072</a></td><td>BXT-51072 weakly inhibits midazolam clearance. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00349">Clobazam</a></td><td>Clobazam decrease the Cmax and AUC of midazolam by approximately 25% of both and increases the Cmax and AUC of its metabolite. Dose adjustment is not necessary. </td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively. </td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01248">Docetaxel</a></td><td>Midazolam may increase the serum levels and toxicity of docetaxel.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Ethotoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fosphenytoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01322">Kava</a></td><td>Kava may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Mephenytoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort may decrease the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Midazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Vemurafenib decreases the AUC (CYP3A4 substrate) by 39%. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit juice slows the product's absorption and significantly increases its bioavailability.</li></ul></td></tr></tbody></table>